A study has demonstrated that both upper tract urothelial carcinoma (UTUC) and urinary bladder urothelial carcinoma (UBUC) have high SLITRK6 expression, rendering it a compelling therapeutic target for the management of UC (124). This evidence concerns the gene SLITRK6 and bladder transitional cell carcinoma.